메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients. Median overall survival not yet reached and is projected to exceed four years, which would surpass osimertinib monotherapy by more than one year. -- Johnson & Johnson today announced final overall survival (OS) results from the Asia patients of the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib monotherapy showed amivantamab plus lazertinib led to a clinically meanin
- 김갑성 기자
- 2025-12-08 09:00
Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

TOKYO, Dec. 8, 2025 -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximately JPY 70 million (USD 460,0001) for the development of a prototype detection test for mpox (formerly known as monkeypox2). Mpox is a viral infectious disease that has been spreading in the Democratic Republic of the Congo (DRC) and across sub-Saharan Africa. According to a situation report by the World Health Organization (WHO), more than 170,000 cases of mpox were confirmed in 141 countries between January 2022 and October 20253. WHO also reported that surveillance d
- 김갑성 기자
- 2025-12-08 09:00
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

SHANGHAI, Dec. 8, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/refractory multiple myeloma (R/R MM) was presented in a poster at the 67th American Society of Hematology5 achieved PR or better. Six patients (ASH) Annual Meeting. The poster was titled "A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refra
- 김갑성 기자
- 2025-12-08 08:15
RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

SINGAPORE, Dec. 8, 2025 -- AI/ML health-tech startup Respiree has received approval from the Health Sciences Authority (HSA) for its 1Bio™AI-Acute toolbox as a Class B software-as-a-medical device (SaMD). The solution is designed to support healthcare professionals in identifying acute inpatient deterioration using AI-enabled machine learning models. Compared to the current standard of care, 1Bio™AI-Acute delivers significantly higher precision in acute deterioration notifications, resulting in fewer false alerts and more efficient clinical support. The 1Bio™AI-Acute system use
- 김갑성 기자
- 2025-12-08 08:00
AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

SINGAPORE, Dec. 8, 2025 -- ChemLex, a next-generation AI-for-science company, today announced the establishment of its global headquarters and self-driving laboratory in Singapore, alongside the close of a USD 45 million funding round led by Granite Asia. Founded in 2022, ChemLex develops AI technologies that radically accelerate chemical discovery for the pharmaceutical industry, significantly reducing time-to-market. In just three and a half years, it has grown to support more than 70 customers worldwide, including six of the world's top ten pharmaceutical companies. This surge refl
- 김갑성 기자
- 2025-12-08 08:00
ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate TLX591 (lutetium (177Lu) rosopatamab tetraxetan) in patients with metastatic castration resistant prostate cancer (mCRPC). The patient was dosed at the Australian Prostate Centre (APC) in Melbourne, Australia. ProstACT Global is the first Phase 3 trial t
- 김갑성 기자
- 2025-12-08 06:08
CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue

SHANGHAI, Dec. 7, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with great pleasure that its independently developed fully human BCMA-targeted CAR-T product, zevorcabtagene autoleucel (zevor-cel, R&D code: CT053), has been included in China's Commercial Health Insurance Innovative Drug Catalogue (2025) (referred to as the "Innovative Drug Catalogue") for the treatment of relapsed/refractory multiple myeloma. The Innovative Drug Catalogue was released today at
- 김갑성 기자
- 2025-12-07 17:21
All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs

HONG KONG, Dec. 7, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the successful inclusion of all five of the Company's self-developed innovative drugs into the updated National Reimbursement Drug List (NRDL) for 2025, released by China's National Healthcare Security Administration (NHSA), effective January 1, 2026. These inclusions cover both newly added indications of previously included drugs, and as well as those participating in national reimbursement negotiations for the first time. With these inclusions, all approved indications for Akeso's five
- 김갑성 기자
- 2025-12-07 14:18
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List

[ 메디채널 김갑성 기자 ] SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that seven of its innovative products have been included in the updated 2025 National Reimbursement Drug List (NRDL). This list features a new indication of TYVYT® (sintilimab injection), and first-time inclusions of SYCUME® (te
- 김갑성 기자
- 2025-12-07 11:40
Leaders Dental Leads Korea's Prosthodontic Market With Large-Scale 300-Pyeong Production Infrastructure and a "Clinically Integrated Collaboration Model"

SEOUL, South Korea, Dec. 7, 2025 -- Leaders Dental Laboratory, a major force driving the digitalization and large-scale transformation of Korea's dental laboratory industry, is solidifying its leadership with a production facility spanning over 300 pyeong. This extensive infrastructure enables high-volume prosthetics manufacturing and exceptional capability in handling complex clinical cases. By combining state-of-the-art digital equipment with highly skilled dental technicians, the company's clinically integrated collaboration model maximizes both accuracy and efficiency in prosthetic produc
- 김갑성 기자
- 2025-12-07 08:00

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분